<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main"></title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Thorsten</forename><forename type="middle">H</forename><surname>Ecke</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">HELIOS Hospital</orgName>
								<address>
									<settlement>Bad Saarow</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katja</forename><surname>Stier</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sabine</forename><surname>Weickm</surname></persName>
							<idno type="ORCID">0000-0001-9797-5362</idno>
							<affiliation key="aff2">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<addrLine>Campus Charité Mitte</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhongwei</forename><surname>Zhao</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<addrLine>Campus Charité Mitte</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Buckendahl</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<addrLine>Campus Charité Mitte</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carsten</forename><surname>Stephan</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<addrLine>Campus Charité Mitte</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Berlin Institute for Urologic Research</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ergin</forename><surname>Kilic</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Klaus</forename><surname>Jung</surname></persName>
							<email>klaus.jung@charite.de</email>
							<affiliation key="aff2">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<addrLine>Campus Charité Mitte</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Berlin Institute for Urologic Research</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Urology, Research Division</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<addrLine>Schumannstr. 20/12</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">7E6C81A710D520419030B801EC61FA50</idno>
					<idno type="DOI">10.1002/cam4.1161</idno>
					<note type="submission">Received: 13 January 2017; Revised: 5 July 2017; Accepted: 17 July 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:44+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Biomarker</term>
					<term>microRNAs</term>
					<term>multivariate analysis</term>
					<term>muscle-invasive bladder cancer</term>
					<term>overall survival</term>
					<term>prognosis</term>
				</keywords>
			</textClass>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Bladder cancer is the fifth most frequent cancer in Europe.</s><s>In 2012, its incidence and annual mortality rate were estimated to 151,200 and 51,400 cases, respectively <ref type="bibr" target="#b0">[1]</ref>.</s><s>Approximately 30% of these patients suffered from muscle-invasive bladder cancer (MIBC) at the time of initial diagnosis <ref type="bibr" target="#b1">[2]</ref>.</s><s>Radical cystectomy (RC) is the gold standard to treat these patients.</s><s>In contrast to patients with nonmuscle-invasive bladder cancer (NMIBC), MIBC patients are subject to a high risk of relapse following RC and cancer-related death.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ORIGINAL RESEARCH</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>miR-199a-3pandmiR-214-3pimprovetheoverallsurvival predictionofmuscle-invasivebladdercancerpatientsafter radicalcystectomy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abstract</head><p><s>To improve the clinical decision-making regarding further treatment management and follow-up scheduling for patients with muscle-invasive bladder cancer (MIBC) after radical cystectomy (RC), a better prediction accuracy of prognosis for these patients is urgently needed.</s><s>The objective of this study was to evaluate the validity of differentially expressed microRNAs (miRNAs) based on a previous study as prognostic markers for overall survival (OS) after RC in models combined with clinicopathological data.</s><s>The expression of six miRNAs (miR-100-5p, miR-130b-3p, miR-141-3p, miR-199a-3p, miR-205-5p, and miR-214-3p) was measured by RT-qPCR in formalin-fixed, paraffin-embedded tissue samples from 156 MIBC patients who received RC in three urological centers.</s><s>Samples from 2000 to 2013 were used according to their tissue availability, with followup until June 2016.</s><s>The patient cohort was randomly divided into a training (n = 100) and test set (n = 56).</s><s>Seventy-three samples from adjacent normal tissue were used as controls.</s><s>Kaplan-Meier, univariate and multivariate Cox regression, and decision curve analyses were carried out to assess the association of clinicopathological variables and miRNAs to OS.</s><s>Both increased (miR-130b-3p and miR-141-3p) and reduced (miR-100-5p, miR-199a-3p, and miR-214-3p) miRNA expressions were found in MIBC samples in comparison to nonmalignant tissue samples (P &lt; 0.0001).</s><s>miR-199a-3p and miR-214-3p were independent markers of OS in Cox regression models with the significant clinicopathological variables age, tumor status, and lymph node status.</s><s>The prediction model with the clinicopathological variables was improved by these two miRNAs in both sets.</s><s>The predictive benefit was confirmed by decision curve analysis.</s><s>In conclusion, the inclusion of both miRNAs into models based on clinical data for the outcome prediction of MIBC patients after RC could be a valuable approach to improve prognostic accuracy.</s></p><p><s>In order to remedy this unsatisfactory situation, serious efforts have recently focused on new therapeutic strategies regarding the application of neoadjuvant and adjuvant chemotherapies <ref type="bibr" target="#b2">[3]</ref>.</s><s>A better risk assessment of patients has been recommended by developing novel predictive/prognostic models <ref type="bibr" target="#b3">[4]</ref>.</s><s>In clinical practice, the therapeutic management of these patients has so far been performed almost exclusively on the basis of clinical data and classical pathological TNM criteria but with few reliable results <ref type="bibr" target="#b3">[4]</ref>.</s><s>There is the hope that the identification of new molecular tissue biomarkers could help to stratify risk groups and determine which patients benefit from adjuvant strategies after surgery <ref type="bibr" target="#b5">[5]</ref>.</s><s>While the results of numerous studies using immunohistochemical biomarkers have been rather disappointing regarding their clinical utilization <ref type="bibr" target="#b6">[6]</ref>, recent reports on gene-based approaches <ref type="bibr" target="#b5">[5,</ref><ref type="bibr" target="#b7">7,</ref><ref type="bibr" target="#b8">8]</ref>, including using microRNAs (miR-NAs) as a new class of mRNA regulators seem to be much more promising <ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref><ref type="bibr" target="#b11">[11]</ref><ref type="bibr" target="#b12">[12]</ref><ref type="bibr" target="#b13">[13]</ref><ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref><ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref>.</s></p><p><s>In a previous study, we identified numerous new differentially expressed miRNAs in fresh-frozen bladder cancer tissue samples in comparison to normal adjacent tissue <ref type="bibr" target="#b18">[18]</ref>.</s><s>It was therefore the objective of this study to evaluate from these 15 previously described miRNAs the usefulness of the most promising miRNAs regarding their potential predictive ability of overall survival (OS) and assess their benefit in comparison to conventional clinicopathological variables in MIBC patients after RC.</s><s>Criteria for the selection of these miRNAs in this study were determinations in a well measurable Cq range and at least twofold median expression differences between the nonmalignant and MIBC tissue samples to allow robust measurements as described before <ref type="bibr" target="#b18">[18]</ref>.</s><s>According to these criteria, both three up-regulated (miR-130b-3p, miR-141-3p, and miR-205-5p) and three down-regulated (miR-100-5p, miR-199a-3p, and miR-214-3p) miRNAs were included in this study.</s><s>To simulate the conditions of clinical practice formalin-fixed, paraffin-embedded (FFPE) tissue samples from three urological centers were analyzed corresponding to a multi-center study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MaterialsandMethods Patientsandtissuesamples</head><p><s>This study included 156 MIBC patients without any neoadjuvant therapy who underwent RC at three urological centers from 2000 to 2013.</s><s>Sixty-four patients (41%) received adjuvant cisplatin-based chemotherapy after RC (Table <ref type="table" target="#tab_1">1</ref>).</s><s>Follow-up data collected until June 2016 were based on medical records and telephone contact with the patients' urologists and patients or family members and death certificates.</s><s>The study was approved by the Hospital Ethics Committee (EA1/153/07; EA1/134/12) in accordance with the Declaration of Helsinki.</s><s>The new STARD and REMARK guidelines were considered <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b20">20]</ref>.</s></p><p><s>The study was carried out on FFPE tissue specimens selected according to their tissue availability and follow-up data (Table <ref type="table" target="#tab_1">1</ref>).</s><s>All samples were finally reviewed by an expert uropathologist (EK) according to the criteria of the International Union Against Cancer and the World Health Organization/International Society of Urological Pathology, as previously reported <ref type="bibr" target="#b18">[18]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RNAextractionandquantitativeRT-PCRof miRNAs</head><p><s>Previously described analytical procedures were applied <ref type="bibr" target="#b18">[18,</ref><ref type="bibr" target="#b21">21]</ref>.</s><s>Hematoxylin/eosin staining was used to identify tumor areas with &gt;80% tumor cells and nonmalignant areas.</s><s>The areas of interest were punch-biopsied with a 1-mm needle device and extracted with the miRNeasy FFPE Kit with an additional DNase I digestion step (Qiagen, Hilden, Germany).</s><s>RT-qPCR measurements and normalizations were performed for the quantification of the miRNAs with TaqMan miRNA assays (Applied Biosystems, Foster City; Table <ref type="table" target="#tab_1">S1</ref>) on a Light Cycler 480 Instrument (Roche Diagnostics, Mannheim, Germany) as previously described including the related documentation with regard to the specific items of the MIQE guidelines <ref type="bibr" target="#b18">[18,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b22">22]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statisticalanalysis</head><p><s>QBasePLUS, v.3.0 software (Biogazelle, Zwijnaarde, Belgium) was used for the analysis of RT-qPCR data.</s><s>Statistical analyses were performed with SPSS 23 (SPSS Inc., Chicago) and MedCalc 16.8.4</s><s>(MedCalc Software, Ostend, Belgium).</s><s>Nonparametric statistical tests (Spearman rank correlation, Mann-Whitney U test, Kruskal-Wallis test) were used.</s><s>The discriminating capacity of miRNAs was assessed by receiver operating characteristics (ROC) analysis and binary logistic regression.</s><s>Kaplan-Meier and Cox regression analyses were performed for OS.</s><s>Decision curve analysis and time-dependent ROC analysis using the statistical approach of cumulative case/ dynamic control and incident case/dynamic control ROC analysis were used to assess the predictive benefit and accuracy of the examined markers <ref type="bibr" target="#b23">[23,</ref><ref type="bibr" target="#b24">24]</ref>.</s><s>The SPSS bias-corrected and accelerated bootstrap method was used for the internal validation using the patient cohort by splitting at random into a training (n = 100) and test set (n = 56).</s><s>P-values &lt;0.05 (two-tailed) were considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Studydesignandpatientcharacteristics</head><p><s>This retrospective study from three urologic departments included 156 MIBC patients that were randomly divided into a training (n = 100) and test set (n = 56).</s><s>For comparison purposes, 73 nonmalignant tissue samples available from these patients were used as controls.</s><s>The characteristics of the study groups are summarized in Table <ref type="table" target="#tab_1">1</ref>.</s><s>There were no statistically significant differences in age and sex between the controls and MIBC patients and between the training and test set with regard to the important clinicopathological variables (Table <ref type="table" target="#tab_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DifferentialexpressionofmicroRNAsin bladdertissueofMIBCpatients</head><p><s>The expression data of the six miRNAs of interest (miR-100-5p, miR-130b-3p, miR-141-3p, miR-199a-3p, miR-205-5p, miR-214-3p) were not statistically different (P = 0.084-0.792)</s><s>between the three centers, so merged data could be evaluated.</s><s>Figure <ref type="figure" target="#fig_0">1</ref> shows that the miRNA expressions differed with high statistical significance (P &lt; 0.0001) between nonmalignant and MIBC samples except miR-205-5p.</s><s>Both increased (miR-130b-3p, miR-141-3p) and reduced levels (miR-100-5p, miR-199a-3p, miR-214-3p) were found in MIBC samples in comparison to nonmalignant tissue samples (P &lt; 0.0001).</s><s>The differential miRNA expressions corresponded to the capacity of the miRNAs to discriminate between nonmalignant and MIBC tissue with miR-130b-3p as the best discriminator (Table <ref type="table" target="#tab_2">S2</ref> and Fig. <ref type="figure" target="#fig_0">S1A and S1B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CorrelationofmiRNAexpressionsto clinicopathologicalvariablesandamong eachother</head><p><s>Correlations were not observed between all miRNAs and sex or age in nonmalignant and tumor samples (r s = 0.108-0.001,</s><s>P-values of 0.180-0.915).</s><s>The clinicopathological variables pT status, histopathological grade, and lymph node status were also not significantly associated with all miRNAs (r s = 0.113-0.004,</s><s>P-values of 0.160-0.957)</s><s>except for miR-130b-3p and miR-205-5p to grade (r s = 0.236 to −0.197, P-values of 0.003 and 0.014).</s><s>These missing associations of miRNAs to clinicopathological variables corresponded to results obtained by the Kruskal-Wallis (pT status, histological grade) and Mann-Whitney test (lymph node status).</s><s>Different correlation coefficients between miRNAs were observed between nonmalignant and MIBC tissue (Table <ref type="table">S3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PrognosticpotentialofmiRNAspredicting postcystectomyoverallsurvivalofMIBC patients</head><p><s>The differential expression and the different correlations between the examined miRNAs indicate their potential as prognostic markers.</s><s>To substantiate the relationship between the clinical outcome of patients and the clinicopathological variables as well as miRNAs, OS was analyzed as the primary clinical endpoint since reliable information about cancer death was not available in all cases.</s><s>OS was Kaplan-Meier survival analyses of clinicopathological variables showed a decreased OS depending on the lymph node metastasis, increased pT status, and age, but OS was not associated with adjuvant chemotherapy (Fig. <ref type="figure" target="#fig_1">S2</ref>).</s><s>These initial data proved the representativeness of the study cohort to evaluate the impact of miRNAs regarding their usefulness as prognostic markers.</s><s>For the internal validation of data, the prognostic performance of all clinicopathological variables and the six miRNAs was calculated using the training and test set (Table <ref type="table" target="#tab_2">2</ref>).</s><s>The variables with P-values &lt;0.10 in univariable analyses for clinicopathological factors (age, pT status, pN status) and for the two miRNAs miR-199a-3p, miR-214-3p were used to build up two models, a full model with all five variables and a reduced model after a backward elimination approach (Table <ref type="table" target="#tab_2">2</ref>).</s><s>This threshold of P-value &lt;0.10 was selected to avoid a possible false negative decision (Type II error) for a potential relevant parameter using a low alpha value in this first step of model building based on univariable Cox regression analysis.</s><s>Both miRNAs also remained as statistically independent variables in the model after backward elimination.</s><s>In addition, the training and test set gave closely corresponding results, indicating that an overfitting bias of results can be largely excluded.</s><s>It is of a special interest that the above mentioned miR-130b-3p as the best discriminator between malignant and nonmalignant bladder tissue failed to provide any prognostic information (Table <ref type="table" target="#tab_2">2</ref>).</s></p><p><s>To confirm the prognostic impact of miR-199-3p and miR-214-3p, C-statistics were performed in a model with the three above-mentioned relevant clinicopathological variables alone (Model CR-1) in comparison to a model (Model CR-2) that also included the relevant miR-199a-3p  1 The training set included 100 and the test set 56 of MIBC patients randomly selected from the cohort characterized in Table <ref type="table" target="#tab_1">1</ref>. 2 Calculations were performed by bootstrapping (2000 resamples) for clinical variables using categorized data as indicated in brackets and for miRNAs using normalized continuous expression values. 3</s><s>The multivariable analysis included all variables with P-values &lt;0.10 obtained in the univariable analysis to avoid a type II error in the first step of model building. 4</s><s>The backward multivariable analysis (P = 0.05 for entry; P = 0.10 for removal) was based on the five variables used in the full multivariable analysis.</s></p><p><s>The 95% CI of the hazard ratios and the P-values of the final model were obtained after bootstrapping (2000 resamples).</s></p><p><s>and miR-214-3p (Table <ref type="table" target="#tab_2">2</ref>).</s><s>Based on the median survival time of about 3 years in the entire cohort (Table <ref type="table" target="#tab_1">1</ref>), the AUCs in cumulative case/dynamic and incident case/ dynamic control ROC analyses were calculated (Fig. <ref type="figure" target="#fig_1">2A  and C</ref>).</s><s>Both approaches resulted in statistically significant higher AUC values in the miRNA-enriched model in comparison to the model with clinicopathological variables alone (AUC of 0.735 vs. 0.645 and 0.709 vs. 0.622; Fig. <ref type="figure" target="#fig_1">2A  and C</ref>).</s><s>The predictive benefit of the two miRNAs is also shown in the decision curve analyses (Fig. <ref type="figure" target="#fig_1">2B and D</ref>).</s></p><p><s>The curves of the model with miRNAs (Model CR-2) are always above the curves of the model with only the clinicopathological variables (Model CR-1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In this retrospective study exclusively focused on the outcome OS, we continued to translate our conclusions drawn from previous miRNA studies in fresh-frozen tissue samples into clinical practice using archived tissue FFPE samples from three centers <ref type="bibr" target="#b18">[18,</ref><ref type="bibr" target="#b21">21]</ref>.</s><s>This study design follows the concept of a discovery-driven global strategy for biomarker search in translational research <ref type="bibr" target="#b25">[25,</ref><ref type="bibr" target="#b26">26]</ref>.</s><s>It is a hypothesis-generating approach that considers the complex situation in clinical settings with regard to all possible variables which could influence the selected clinical end point.</s><s>We previously postulated four development phases of biomarker assays for clinical practice, namely, first, the discovery and selection of potential biomarkers, second, the assay setup and performance control, third, the validation by clinical assessment, and finally the validation by clinical usability <ref type="bibr" target="#b27">[27]</ref>.</s><s>According to this scheme, we would classify our present study into the third phase.</s></p><p><s>The study results suggest that miR-199a-3p and miR-214-3p are helpful biomarkers to enhance the OS prediction in comparison with clinicopathological data alone in MIBC patients after RC and improve therefore further decisionmaking both for clinicians and patients.</s><s>Numerous miRNA studies in bladder cancer identified histological grade and pT classification dependent miR expressions and proved typical miRNA alterations related to the two divergent pathways found in the development of NMIBC and MIBC (reviewed by Guancial et al. <ref type="bibr" target="#b28">[28]</ref>).</s><s>As already noted in the introduction, only a few studies used miRNAs as prognostic and predictive biomarkers in bladder cancer patients but mostly in NMIBC patients <ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref><ref type="bibr" target="#b11">[11]</ref><ref type="bibr" target="#b12">[12]</ref><ref type="bibr" target="#b13">[13]</ref><ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref><ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref>.</s><s>Different miRNAs were suggested as prognostic biomarkers for MIBC patients as combinations of four (let-7c, miR-125b-1, miR193a, miR-99a) <ref type="bibr" target="#b17">[17]</ref>, three (miR-9, miR-183, miR-200b) <ref type="bibr" target="#b13">[13]</ref>, and two miRNAs (miR-143, miR-145) <ref type="bibr" target="#b15">[15]</ref>, but also as predictive markers for the response to cisplatin-based adjuvant chemotherapy <ref type="bibr" target="#b11">[11]</ref>.</s><s>However, none of these studies performed multivariable analyses or verified the examined miRNAs as independent markers.</s></p><p><s>In a recent study, Schubert et al. summarized the inconsistent data situation of miRNAs as prognostic markers in urological tumors <ref type="bibr" target="#b29">[29]</ref>.</s><s>Different strategies to identify suitable prognostic miRNAs, the use of various analytical techniques, the insufficient sample size of study groups with lack of internal/external validations and multivariable analyses are reasons for the partially contradictory results if miRNAs have been applied as prognostic biomarkers in bladder cancer <ref type="bibr" target="#b29">[29]</ref>.</s><s>Furthermore, beside the application of different clinical endpoints, studies have been also performed in cohorts including both MIBC and NMIBC patients without separate data evaluation or missing multivariable analysis <ref type="bibr" target="#b16">[16,</ref><ref type="bibr" target="#b30">30]</ref>.</s><s>Distinct molecular alterations including different miRNA profiles in noninvasive and invasive tumors may facilitate discrimination between both bladder cancer entities <ref type="bibr" target="#b9">[9,</ref><ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32]</ref>, but this aspect needs a special attention for the prognostic assessment of miR-NAs.</s><s>The different miRNA expression, partly characterized by an opposite expression between nonmalignant, NMIBC, and MIBC tissue as for example in the case of miR-141 and miR-205 <ref type="bibr" target="#b18">[18]</ref>, could hamper a reliable prediction of the clinical outcome in multivariable Cox regression analyses in connection with clinicopathological factors.</s><s>This possible bias was impressively illustrated by the example of miR-214 <ref type="bibr" target="#b33">[33]</ref>.</s><s>This miRNA was shown to be an independent factor of recurrence-free survival and OS in the MIBC cohort but failed if MIBC and NMIBC patients were analyzed as a combined group.</s><s>To avoid all these possible errors, we studied only one bladder cancer entity, MIBC patients.</s><s>We used FFPE samples from the practical point of view with a sufficient sample size and number of events for carrying out multivariable analyses, and performed a twofold internal validation approach by using a training and test set with bootstrapping calculation of continuous instead of categorized data according to the REMARK guidelines to achieve a high level of statistical power.</s></p><p><s>The up-and down-regulated expression of the six selected miRNAs primarily found in fresh-frozen MIBC versus nonmalignant tissue in our previous study <ref type="bibr" target="#b18">[18]</ref> was confirmed in the FFPE samples in this study reaching at least by a median twofold change, except for miR-205-5p (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Moreover, three points should be emphasized in relation to assessment of outcome as the main aim of this study: the missing or only weak correlations of miRNAs with the clinicopathological risk factors, the different correlation coefficients among the miRNAs described in the Results, and the failure of miR-130-3p as the best miRNA discriminator between nonmalignant and malignant tissue to provide any prognostic information.</s><s>The striking hallmark of the uncorrelated differential expression of miRNAs to known disease variables characterizes the miRNAs here examined as potential orthogonal biomarkers <ref type="bibr" target="#b34">[34]</ref>.</s><s>This particular feature of orthogonal markers appears as a precondition that such markers can influence the clinical endpoint of OS independent of the conventional clinicopathological variables and must therefore be included as necessary independent variables in a corresponding prognostic model.</s><s>The evidence of such an independent variable in multivariable analysis additionally promotes the discovery of novel downstream targets and their associated pathways <ref type="bibr" target="#b34">[34]</ref>.</s><s>Our study proved that both miR-199a-3p and miR-214-3p remained such independent variables in multivariable Cox regression models (Table <ref type="table" target="#tab_2">2</ref>).</s><s>The predictive accuracy of OS probability based only on the conventional clinicopathological variables could be improved by these two miRNAs.</s><s>This clinical benefit was verified by the decision curve analysis and also by the time-dependent ROC analysis if the two miRNAs were included into the model with only conventional clinicopathological variables (Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s>The combined use of the clinicopathological variables and the expression data of the two microRNAs measured in tissue samples from cystectomy specimens offers the opportunity to develop a risk scoring system in prospective studies as result of the clinical usability of this approach.</s><s>This would correspond to the final development phase of biomarker assay for clinical practice as suggested above <ref type="bibr" target="#b27">[27]</ref>.</s><s>In contrast to miR-199a-3p and miR-214-3p, miR-130b-3p as the best discriminator between nonmalignant and cancer tissue did not offer any prognostic information.</s><s>The prognostic information could also not be confirmed for miR-141-3p and miR-205-5p, which were previously shown only in Kaplan-Meier analyses, but not in multivariable Cox regression analyses <ref type="bibr" target="#b16">[16,</ref><ref type="bibr" target="#b18">18]</ref>.</s><s>The reason might be that both miRNAs show an opposite expression in NMIBC and MIBC and the mentioned studies were performed in combined cohorts of NMIBC and MIBC patients.</s></p><p><s>Up to now there are only few investigations concerning the role of miR-199a-3p and miR-214-3p with special focus on bladder cancerogenesis and its neoplastic progression.</s><s>miR-199a derives from two loci of the human genome, mir-199a-1 of chromosome 19 (cytogenetic location 19p13.2) and mir-199a-2 of chromosome 1 (cytogenetic location 1q24.3).</s><s>These two loci encode mir-199a, which generate the two mature miRNAs, miR-199a-3p and miR-199a-5p.</s><s>Depending on the underlying malignancy, miR-199a-3p acts both as oncogene being upregulated like in gastric and colorectal cancer <ref type="bibr" target="#b35">[35,</ref><ref type="bibr" target="#b36">36]</ref> and as tumor suppressor being down-regulated like in renal cell cancer, hepatocellular carcinoma, prostate cancer or bladder cancer <ref type="bibr" target="#b37">[37]</ref><ref type="bibr" target="#b38">[38]</ref><ref type="bibr" target="#b39">[39]</ref>.</s><s>The down-regulated expression of miR-199a-3p in bladder cancer was also described as tumor suppressive miRNA by other groups but not further evaluated as prognostic marker <ref type="bibr" target="#b31">[31,</ref><ref type="bibr" target="#b32">32,</ref><ref type="bibr" target="#b40">40,</ref><ref type="bibr" target="#b41">41]</ref>.</s><s>After we had finished our study, Sakaguchi et al. <ref type="bibr" target="#b42">[42]</ref> recently showed that the expression of all four miR-199 family members consisting of miR-199b-3p, and miR-199b-5p in addition to the two above-mentioned miR-199a forms, was down-regulated in bladder cancer.</s><s>The decreased expression of the miRNAs was found to be associated with a poor OS of patients shown in Kaplan-Meier analyses but it was not additionally assessed in multivariable Cox regression analyses <ref type="bibr" target="#b42">[42]</ref>.</s><s>It was shown that these miRNAs act as tumor suppressors by targeting ITGA3 (integrin subunit α3).</s><s>However, the increased ITGA3 mRNA expression was not significantly associated with the survival of patients <ref type="bibr" target="#b42">[42]</ref>.</s><s>This phenomenon of missing link between a differentially expressed miRNA and its verified target gene with regard to a clinical endpoint is understandable, bearing in mind that miR-199a targets numerous genes that could affect the prognosis of patients.</s><s>For example, miR-199a-3p was validated as tumor suppressive miRNA in other cancers like prostate cancer targeting AURKA (aurora kinase A) <ref type="bibr" target="#b39">[39]</ref>, in renal cell cancer GSK3B (glycogen synthase kinase 3 beta) <ref type="bibr" target="#b37">[37]</ref>, and in hepatocellular carcinoma HGF (hepatocyte growth factor), MMP2 (matrix metallopeptidase 2), VEGFA (vascular endothelial growth factor A), and its corresponding receptors <ref type="bibr" target="#b43">[43]</ref>.</s><s>So far, these targets have not been examined in bladder cancer as potential points of action for miR-199a-3p.</s><s>However, all these genes play a significant role in signaling pathways of angiogenesis, invasion, and metastasis in cancer as shown in the software DIANA-mirPath (http://diana.imis.</s><s>athena-innovation.gr/DianaTools)</s><s><ref type="bibr" target="#b44">[44]</ref>.</s><s>Moreover, it is of particular interest that the second relevant prognostic mature miRNA in our study, miR-214-3p, derives from the stem loop sequence of mir-214 that clusters with mir-199a-2 of the same chromosome locus 1q24.3.</s><s>Similar to miR-199a-3p, miR-214-3p acts, depending on the cancer types, oncogenic in osteosarcoma and oral cancer <ref type="bibr" target="#b45">[45,</ref><ref type="bibr" target="#b46">46]</ref> but tumor suppressive in breast, cervical, esophageal, and bladder cancers <ref type="bibr" target="#b33">[33,</ref><ref type="bibr" target="#b47">[47]</ref><ref type="bibr" target="#b48">[48]</ref><ref type="bibr" target="#b49">[49]</ref><ref type="bibr" target="#b50">[50]</ref><ref type="bibr" target="#b51">[51]</ref>.</s><s>Based on our previous expression study <ref type="bibr" target="#b18">[18]</ref>, Wang et al. <ref type="bibr" target="#b33">[33]</ref> characterized the down-regulated miR-214-3p as a suppressive miRNA.</s><s>This miRNA functions as an independent factor of OS in MIBC patients, targeting the oncogene PDRG1 (p53 and DNA damage regulated 1).</s><s>SLC34A2 (solute carrier family 34 member 2) and several genes of the epithelial-mesenchymal transition and the NGAL/MMP-9 (lipocalin 2/metallopeptidase 9) pathways were also verified or predicted to be negatively regulated by miR-214-3p in the process of bladder cancer development <ref type="bibr" target="#b50">[50,</ref><ref type="bibr" target="#b51">51]</ref>.</s></p><p><s>The possible biological significance of the co-expression of the two down-regulated miR-199a and miR-214 was shown in testicular germ cell tumor <ref type="bibr" target="#b52">[52]</ref>.</s><s>A self-regulatory network of the two microRNAs together with PSMD10 (proteasome 26S subunit, non-ATPase 10), TP53 (tumor protein p53), and DNTM1 (DNA methyltransferase 1) was identified whose dysfunction results in tumor progression.</s><s>As mentioned above, these two microRNAs also act as regulators of numerous target genes that have been already validated so far in urinary bladder and other solid cancers (target characteristics are given in Table <ref type="table">S4</ref>).</s><s>Moreover, based on our data of prognostic relevance of miR-199a-3p and miR-214-3p, the view is supported that such a regulatory network or at least a cooperative action of the micro-RNAs as shown in other cancer examples <ref type="bibr" target="#b53">[53]</ref> could also exist in bladder cancer.</s><s>A detailed investigation of the functional role of the two miRNAs would be worthwhile but was beyond the scope of this study.</s><s>On the other hand, we share the view of Burke <ref type="bibr" target="#b54">[54]</ref> that the functional role of biomarker might be, in a certain sense, useful to explain the biological rationale of biomarker but is not decisive for its clinical usability.</s><s>Under this translational aspect, the primary focus in the search for a truly reliable biomarker has to be directed more toward the clinical benefit of the potential new biomarker in comparison to the so far used procedures in clinical practice.</s></p><p><s>Limitations of the study are, despite our precautions for bias-free analyses using the internal validation by a training and test sets with bootstrapping, its retrospective nature on overall and not cancer-specific survival, the lack of external validation, and the biomarker-focused aspect without elucidating the molecular mechanisms as argued above.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>In summary, our study identified miR-199a-3p and miR-214-3p as independent prognostic biomarkers for the prediction of OS in MIBC patients after RC.</s><s>Their inclusion in prognostic models based on relevant clinicopathological risk factors improved the predictive accuracy.</s><s>Such enhanced information of combined clinicopathological and molecular data could support clinicians in their decisionmaking in the treatment management and follow-up scheduling after RC.</s><s>It could also help patients who wish to be kept fully informed about their further life expectancy to plan and manage their remaining lifetime.</s><s>Thus, further efforts through complimentary multicenter prospective randomized studies would be worth to translate these biomarkers into clinical practice as suggested.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .F</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Differential expression of miRNAs (A: miR-100-5p; B: miR-130-3p; C: miR-141-3p; D: miR-199-3p; E: miR-205-5p; F: miR-214-3p) in nonmalignant bladder tissue (n = 73) and muscle-invasive bladder cancer (MIBC) tissue samples (n = 156).</s><s>Expression values were normalized against the reference miRNA signature (miR-101-3p, miR-148b-5p, miR-125a-5p, and miR-151-5p) as previously described<ref type="bibr" target="#b21">[21]</ref>.</s><s>Medians and interquartile ranges are indicated with statistical significances calculated by the Mann-Whitney U test.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Improved survival predictive accuracy by including miR-199a-3p and miR-214-3p (Model CR-2) in a model with only clinicopathological variables age, pT status, and lymph node metastasis (Model CR-1).</s><s>Areas under the time-dependent ROC curve (AUC) of the two models were calculated based on (A) a cumulative case (n = 78)/dynamic control (n = 41) approach at 36 months after surgery as well as on (C) an incident case (n = 99)/dynamic control (n = 57) approach [24].</s><s>AUCs of Model CR-2 showed statistically significant higher values in both approaches in comparison with Model CR-1 [Model CR-2 vs. Model CR-1 in (A) with 0.735 (0.624-0.827) vs. 0.645 (0.545-0.746),</s><s>P = 0.031 and in (C) with 0.709 (0.637-0.796) vs. 0.622 (0.534-0.716),</s><s>P = 0.011].</s><s>Curves in the decision curve analysis confirmed (B and D) the benefit of including the two miRNAs in the model based only on clinicopathological variables.</s></p></div></figDesc><graphic coords="6,64.36,221.14,458.10,399.31" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Clinicopathological characteristics of the study groups.</s></p></div></figDesc><table><row><cell>Variable</cell><cell>Controls 1 (n = 73)</cell><cell>All MIBC patients</cell><cell>P 2</cell><cell>Training set</cell><cell>Test set</cell><cell>P 2</cell></row><row><cell></cell><cell></cell><cell>(n = 156)</cell><cell></cell><cell>(n = 100)</cell><cell>(n = 56)</cell><cell></cell></row><row><cell>Age [year, median (range)]</cell><cell>69 (44-81)</cell><cell>69 (37-82)</cell><cell>0.689</cell><cell>69 (37-82)</cell><cell>68 (45-81)</cell><cell>0.283</cell></row><row><cell>Gender (n; %)</cell><cell></cell><cell></cell><cell>0.401</cell><cell></cell><cell></cell><cell>0.241</cell></row><row><cell>Female</cell><cell>7 (10)</cell><cell>23 (15)</cell><cell></cell><cell>12 (12)</cell><cell>11 (20)</cell><cell></cell></row><row><cell>Male</cell><cell>66 (90)</cell><cell>133 (85)</cell><cell></cell><cell>88 (88)</cell><cell>45 (80)</cell><cell></cell></row><row><cell>pT status (n; %)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pT2</cell><cell></cell><cell>47 (30)</cell><cell></cell><cell>32</cell><cell>15</cell><cell>0.759</cell></row><row><cell>pT3</cell><cell></cell><cell>78 (50)</cell><cell></cell><cell>48</cell><cell>30</cell><cell></cell></row><row><cell>pT4</cell><cell></cell><cell>31 (20)</cell><cell></cell><cell>20</cell><cell>11</cell><cell></cell></row><row><cell>Grade (n; %)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>G2</cell><cell></cell><cell>14 (9)</cell><cell></cell><cell>10</cell><cell>4</cell><cell>0.463</cell></row><row><cell>G3</cell><cell></cell><cell>140 (90)</cell><cell></cell><cell>88</cell><cell>52</cell><cell></cell></row><row><cell>G4</cell><cell></cell><cell>2 (1)</cell><cell></cell><cell>2</cell><cell>-</cell><cell></cell></row><row><cell>pN status (n; %)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pN0/Nx</cell><cell></cell><cell>102 (65)</cell><cell></cell><cell>69</cell><cell>33</cell><cell>0.222</cell></row><row><cell>pN1</cell><cell></cell><cell>54 (35)</cell><cell></cell><cell>31</cell><cell>23</cell><cell></cell></row><row><cell>Adjuvant therapy (n; %)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell></cell><cell>64 (41)</cell><cell></cell><cell>43</cell><cell>21</cell><cell>0.611</cell></row><row><cell>No</cell><cell></cell><cell>92 (59)</cell><cell></cell><cell>57</cell><cell>35</cell><cell></cell></row><row><cell>Sample source (n; %) 3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Center 1</cell><cell>51 (70)</cell><cell>101 (65)</cell><cell>0.486</cell><cell>62</cell><cell>39</cell><cell>0.598</cell></row><row><cell>Center 2</cell><cell>7 (10)</cell><cell>24 (15)</cell><cell></cell><cell>16</cell><cell>8</cell><cell></cell></row><row><cell>Center 3</cell><cell>15 (20)</cell><cell>31 (20)</cell><cell></cell><cell>22</cell><cell>9</cell><cell></cell></row><row><cell>Follow-up after surgery</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Time [month; median (range)]</cell><cell></cell><cell>28 (1-180)</cell><cell></cell><cell>34 (1-180)</cell><cell>23 (1-163)</cell><cell>0.503</cell></row><row><cell>Death events (n; %)</cell><cell></cell><cell>99 (63)</cell><cell></cell><cell>67 (67)</cell><cell>32 (57)</cell><cell>0.230</cell></row><row><cell>Survival time [month, median (95% CI)]</cell><cell></cell><cell>34 (24-49)</cell><cell></cell><cell>35 (24-49)</cell><cell>26 (16-106)</cell><cell>0.589</cell></row></table><note><p><s>CI, confidence interval; G, histopathological grade; MIBC, muscle-invasive bladder cancer; pN, lymph node status; pT, pathological tumor classification.1Controlsrefertononmalignanttissue</s><s>samples obtained from MIBC patients as described in Methods and Materials.2Statisticaltests:Mann-Whitney</s><s>U test; Chi-square or Fisher's exact test, and log-rank test, Kaplan-Meier analysis.3Center</s><s>1: Campus Benjamin Franklin, University Hospital Charité; Center 2: Campus Mitte, University Hospital Charité; Center 3: Helios Clinical Center, Bad Saarow.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Cox proportional hazard regression analyses of clinicopathological factors and miRNAs for predicting overall survival in MIBC patients after radical cystectomy in training and test set 1 .</s></p></div></figDesc><table><row><cell>Variable 2</cell><cell>Training set (n = 100)</cell><cell></cell><cell>Test set (n = 56)</cell><cell></cell></row><row><cell></cell><cell>HR (95% CI)</cell><cell>P-value</cell><cell>HR (95% CI)</cell><cell>P-value</cell></row><row><cell>Univariable analysis</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age (&lt;69/≥69 years)</cell><cell>1.56 (0.94-2.53)</cell><cell>0.087</cell><cell>1.98 (0.99-3.97)</cell><cell>0.055</cell></row><row><cell>Sex (female/male)</cell><cell>1.61 (0.73-3.53)</cell><cell>0.283</cell><cell>1.20 (0.45-3.62)</cell><cell>0.659</cell></row><row><cell>pT status (pT2,3,4)</cell><cell>1.46 (1.04-2.04)</cell><cell>0.029</cell><cell>1.64 (0.83-3.44)</cell><cell>0.098</cell></row><row><cell>Grade (G2/G3-4)</cell><cell>0.96 (0.46-2.01)</cell><cell>0.904</cell><cell>1.50 (0.29-23.9)</cell><cell>0.529</cell></row><row><cell>pN status (N0,Nx/N1)</cell><cell>2.01 (1.23-3.28)</cell><cell>0.005</cell><cell>1.96 (0.94-4.65)</cell><cell>0.053</cell></row><row><cell>Adjuvant therapy</cell><cell>1.38 (0.85-2.22)</cell><cell>0.193</cell><cell>0.89 (0.44-1.79)</cell><cell>0.741</cell></row><row><cell>miR-100-5p</cell><cell>0.99 (0.87-1.23)</cell><cell>0.853</cell><cell>0.93 (0.60-1.12)</cell><cell>0.680</cell></row><row><cell>miR-130b-3p</cell><cell>0.99 (0.77-1.27)</cell><cell>0.918</cell><cell>1.02 (0.53-1.85)</cell><cell>0.643</cell></row><row><cell>miR-141-3p</cell><cell>0.93 (0.70-1.25)</cell><cell>0.633</cell><cell>0.76 (0.39-1.24)</cell><cell>0.306</cell></row><row><cell>miR-199a-3p</cell><cell>0.53 (0.30-0.91)</cell><cell>0.023</cell><cell>0.49 (0.18-0.96)</cell><cell>0.042</cell></row><row><cell>miR-205-5p</cell><cell>1.02 (0.92-1.14)</cell><cell>0.720</cell><cell>1.16 (0.81-1.95)</cell><cell>0.302</cell></row><row><cell>miR-214-3p</cell><cell>1.80 (1.12-2.89)</cell><cell>0.015</cell><cell>2.96 (1.29-6.75)</cell><cell>0.005</cell></row><row><cell>Multivariable analysis, full model 3</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age</cell><cell>1.49 (0.88-2.51)</cell><cell>0.137</cell><cell>1.65 (0.77-3.53)</cell><cell>0.255</cell></row><row><cell>pT status</cell><cell>1.45 (1.01-2.07)</cell><cell>0.045</cell><cell>1.85 (0.99-3.43)</cell><cell>0.053</cell></row><row><cell>pN status</cell><cell>1.62 (0.97-2.71)</cell><cell>0.064</cell><cell>2.26 (1.01-5.04)</cell><cell>0.046</cell></row><row><cell>miR-199a-3p</cell><cell>0.57 (0.32-1.02)</cell><cell>0.058</cell><cell>0.32 (0.11-0.94)</cell><cell>0.039</cell></row><row><cell>miR-214-3p</cell><cell>1.79 (1.12-2.85)</cell><cell>0.015</cell><cell>3.30 (1.11-9.77)</cell><cell>0.031</cell></row><row><cell>Multivariable analysis, backward elimination 4</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pT status</cell><cell>1.42 (1.01-1.98)</cell><cell>0.042</cell><cell>1.81 (0.96-3.39)</cell><cell>0.065</cell></row><row><cell>pN status</cell><cell>1.67 (1.01-2.77)</cell><cell>0.052</cell><cell>2.32 (1.06-5.09)</cell><cell>0.035</cell></row><row><cell>miR-199a-3p</cell><cell>0.53 (0.27-0.89)</cell><cell>0.026</cell><cell>0.35 (0.13-0.91)</cell><cell>0.032</cell></row><row><cell>miR-214-3p</cell><cell>1.88 (1.21-3.51)</cell><cell>0.005</cell><cell>3.29 (1.24-8.74)</cell><cell>0.017</cell></row><row><cell cols="5">CI, confidence interval; G, histopathological grading; HR, hazard ratio; MIBC, muscle-invasive bladder cancer; miR, microRNA; pT, pathological tumor</cell></row><row><cell>classification; pN, lymph nodal status.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2017 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2017 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd. Survival Prediction of Bladder Cancer by microRNAs T. H. Ecke et al.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The support by the Berliner Krebsgesellschaft (Grant no.</s><s>JUFF201403), the SONNENFELD-STIFTUNG Berlin (Grant no.25.3.2015/GB/co), and the Foundation of Urologic Research (Grant no.</s><s>SKJ_02_2014) is gratefully acknowledged.</s><s>The grant sponsors had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ConflictofInterest</head><p><s>None declared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SupportingInformation</head><p><s>Additional supporting information may be found in the online version of this article: Table <ref type="table">S1</ref>.</s><s>Details of the TaqMan microRNA assays.</s><s>Figure <ref type="figure">S1</ref>.</s><s>Discriminative capacity of miRNA models.</s><s>Table <ref type="table">S2</ref>.</s><s>Receiver-operating characteristics analyses of miRNAs and their combinations with comments to Figure <ref type="figure">S1</ref> and data in Table <ref type="table">S2</ref>.</s></p><p><s>Table <ref type="table">S3</ref>.</s><s>Spearman correlation coefficients of miRNApairs with comments to the data.</s></p><p><s>Figure <ref type="figure">S2</ref>.</s><s>Kaplan-Meier analyses of overall survivals of muscle-invasive bladder cancer patients after radical cystectomy in association with clinicopathological variables.</s></p><p><s>Table <ref type="table">S4</ref>.</s><s>Target genes of miR-199a-3p and miR-214-3p.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Steliarova-Foucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lortet-Tieulent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Coebergh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Comber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1374" to="1403" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Witjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Comperat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Cowan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lebret</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. Urol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="778" to="792" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Witjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lebret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Comperat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Cowan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Bruins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. Urol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="462" to="475" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Kluth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Bochner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Catto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature</title>
		<author>
			<persName><forename type="first">A</forename><surname>Lerner</surname></persName>
		</author>
		<author>
			<persName><surname>Stenzl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. Urol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="238" to="253" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leicht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Danenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">V</forename><surname>Danenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neoplasia</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="628" to="636" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Biomarkers in bladder cancer: translational and clinical implications</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Davison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Beltran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Montironi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Oncol. Hematol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="73" to="111" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A four-gene signature predicts disease progression in muscle invasive bladder cancer</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="478" to="485" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Mitra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ghadessi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Erho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Vergara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alshalalfa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page">290</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Distinct microRNA alterations characterize high-and low-grade bladder cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Catto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Miah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Owen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bryant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dudziec</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="8472" to="8481" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A microRNA expression ratio defining the invasive phenotype in bladder tumors</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Neely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Rieger-Christ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Neto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Eroshkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Patel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urol. Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="39" to="48" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nordentoft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Birkenkamp-Demtroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Agerbaek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Theodorescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Ostenfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hartmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Med. Genomics</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">40</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Puerta-Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Garcia-Baquero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ocana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alvarez-Mugica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Alvarez-Ossorio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Pathol</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="page" from="1808" to="1815" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Pignot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cizeron-Clairac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Susini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tozlu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vieillefond</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="2479" to="2491" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Andrew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Marsit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Schned</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Seigne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Kelsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Moore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1158" to="1166" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Uncovering the clinical Survival Prediction of Bladder Cancer by microRNAs T. H. Ecke et al. utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment</title>
		<author>
			<persName><forename type="first">M</forename><surname>Avgeris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mavridis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tokas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stravodimos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Fragoulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scorilas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Carcinogenesis</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="528" to="537" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">F</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">X</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="877" to="883" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Q</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Z</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="8159" to="8166" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">MicroRNA profiling identifies candidate miRNAs for bladder cancer diagnosis and clinical outcome</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ratert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-A</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lioudmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-J</forename><surname>Mollenkopf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Wagner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Mol. Diagn</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="695" to="705" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Taube</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e1001216</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Bossuyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Reitsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Bruns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Gatsonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Glasziou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Irwig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Chem</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="1446" to="1452" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Reference miRNAs for miRNAome analysis of urothelial carcinomas</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ratert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-A</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-J</forename><surname>Mollenkopf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e39309</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Bustin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Benes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Garson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hellemans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huggett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kubista</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Chem</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="611" to="622" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Decision curve analysis: a novel method for evaluating prediction models</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Vickers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Elkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med. Decis. Making</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="565" to="574" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Survival model predictive accuracy and ROC curves</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Heagerty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="92" to="105" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Translational medicine: a two-way road</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Marincola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">What&apos;s next in translational medicine?</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Littman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Di</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Plebani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Marincola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Sci</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="217" to="227" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The translational potential of microRNAs as biofluid markers of urologic tumors</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fendler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stephan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Yousef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kristiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Urol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="734" to="752" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The evolving understanding of microRNA in bladder cancer</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Guancial</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Berman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urol. Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page">41</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: where do we stand in biomarker development?</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schubert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Junker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Heinzelmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Cancer Res. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="1673" to="1695" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Transl. Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="849" to="854" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro</title>
		<author>
			<persName><forename type="first">L</forename><surname>Dyrskjot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Ostenfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bramsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Silahtaroglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ramanathan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="4851" to="4860" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Predicting progression of bladder urothelial carcinoma using microRNA expression</title>
		<author>
			<persName><forename type="first">E</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Baniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Spector</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Faerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Meiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Aharonov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="1027" to="1034" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0118086</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The search for new cardiovascular biomarkers</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Gerszten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">451</biblScope>
			<biblScope unit="page" from="949" to="952" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">MiR-199a-3p promotes gastric cancer progression by targeting ZHX1</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yu ; Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">588</biblScope>
			<biblScope unit="page" from="4504" to="4512" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers</title>
		<author>
			<persName><forename type="first">D</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Shen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med. Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page">378</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3beta</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tsukigi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bilim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yuuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ugolkov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Naito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nagaoka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="page" from="189" to="197" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Amr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Ezzat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Elhosary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Hegazy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Fahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Kamel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gene</title>
		<imprint>
			<biblScope unit="volume">575</biblScope>
			<biblScope unit="page" from="66" to="70" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Pathol</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="1541" to="1549" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Identification of novel microRNA targets based on microRNA signatures in bladder cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ichimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Enokida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Okuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kunimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chiyomaru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kawamoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="345" to="352" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events</title>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e22570</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sakaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yoshino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yonemori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Miyamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sugita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Matsushita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="1077" to="1087" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roychoudhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gorain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e2706</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Vlachos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kostoulas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vergoulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Georgakilas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reczko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maragkakis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="W498" to="W504" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Overexpression of miR214 promotes the progression of human osteosarcoma by regulating the Wnt/betacatenin signaling pathway</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">B</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Qiu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Med. Rep</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1884" to="1892" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">X</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genet. Mol. Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">16019327</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">478</biblScope>
			<biblScope unit="page" from="337" to="342" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells</title>
		<author>
			<persName><forename type="first">R</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Men</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">484</biblScope>
			<biblScope unit="page" from="623" to="630" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1</title>
		<author>
			<persName><forename type="first">P</forename><surname>Phatak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Byrnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mansour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2087" to="2097" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Falzone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Candido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Basile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scalisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mccubrey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="72758" to="72766" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity</title>
		<author>
			<persName><forename type="first">W</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">S</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e2581</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Suen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Chan</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="page">6413</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Cooperative effect of miR-141-3p and miR-145-5p in the regulation of targets in clear cell renal cell carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Liep</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kilic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Busch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rabien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">e0157801</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Predicting clinical outcomes using molecular biomarkers</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Burke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomark. Cancer</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="89" to="99" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
